Nova In Silico prospectively predicts LDL‑C outcomes of Merck’s Phase 3 CORALreef Lipids trial using an in...
LYON, FRANCE (November 14th, 2025) – Nova In Silico, (“Nova”), a health-tech company pioneering digital twins in healthcare with its unique causal AI jinkōⓇ platform supporting teams with...